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Eradication of Established Tumors
by CD81 T Cell Adoptive Immunotherapy
competent immune system to tumor tissue can result
in the generation of specific anti-tumor effectors (Dra-
noff et al., 1993; Boon et al., 1994; Mayordomo et al.,
Holly L. Hanson,* David L. Donermeyer,*
Hiroaki Ikeda,* J. Michael White,* Vijay Shankaran,*
Lloyd J. Old,² Hiroshi Shiku,³ Robert D. Schreiber,*
1995; Toes et al., 1998) but assume the risk of inducingand Paul M. Allen*§
tolerance or autoimmunity (Toes et al., 1996; Overwijk*Department of Pathology and Center for Immunology
et al., 1999). Adoptive immunotherapy potentially pro-Washington University School of Medicine
vides a controlled and highly specific stratagem for theSt. Louis, Missouri 63110
treatment of cancer. However, in humans, adoptive im-²Ludwig Institute for Cancer Research
munotherapy has so far been plagued by suboptimalNew York, New York 10158
response rates, limited response durations, and extreme³Mie University School of Medicine toxicities associated with the simultaneous administra-
2nd Department of Internal Medicine tion of high doses of IL-2 necessary for maintaining cell
2-174 Edobashi survival (Rosenberg et al., 1994). Successful elimination
Tsu, Mie 514 of experimental tumors in animal models by utilization
Japan of adoptive immunotherapy has also required repeated
administration of IL-2, adjuvant, and/or immunosup-
pression of the tumor-bearing host (Rosenstein et al.,
Summary 1984; Hu et al., 1993; Vierboom et al., 1997; Overwijk et
al., 1998; Granziero et al., 1999).
We generated the DUC18 T cell receptor transgenic Many experimental tumor systems have been used
to study the immune response in tumor-bearing animals.mouse expressing an H-2Kd -restricted transgenic T
These systems have utilized tumors transfected withcell receptor specific for the syngeneic CMS5 fibro-
model antigens such as OVA (Minev et al., 1994; Shrikantsarcoma rejection antigen mutated ERK2(136±144).
and Mescher, 1999), alloantigens (Wick et al., 1997), orDUC18 mice were capable of specifically eliminating
immunogenic viral or bacterial components (Staveley-lethal CMS5 tumor challenges, and transfer of DUC18
O'Carroll et al., 1998; Marzo et al., 1999; Ochsenbeinsplenocytes to naive nontransgenic recipients con-
et al., 1999) as well as tumors transfected to secreteferred protection from subsequent and established
cytokines (Bannerji et al., 1994) or express costimulatoryCMS5 tumor burdens. Eradication of established tu-
molecules (Sarma et al., 1999). Despite numerous stud-mor burdens by adoptive transfer of DUC18 spleno-
ies utilizing these systems, the therapeutic value of im-cytes was dose and time dependent. Transferred tu-
munotherapy has not been definitively established. We
mor-specific T cells remained functional in vivo and sought to create a system that would better model hu-
capable of rejecting small tumors even in the presence man malignancy and that would allow examination of
of large, established tumor burdens. These findings the function and immunotherapeutic potential of tumor-
highlight the kinetic battle between tumor growth and specific T cells in the presence of an unmanipulated
the production of a tumor-specific response and have tumor naturally expressing a physiologically relevant tu-
critical implications for effective adoptive immuno- mor-rejection antigen.
therapy. This report is the initial description of a novel murine
TCR transgenic model system utilizing the methylcho-
Introduction lanthrene-induced fibrosarcoma CMS5. The tumor-
rejection antigen for CMS5 was previously identified as
Environmental carcinogens and specific genetic muta- an H-2Kd binding nonamer peptide derived from a mutated
tions have been implicated in the development of soft ERK2 kinase (Ikeda et al., 1997). While it is not clear
tissue sarcomas, which account for 1% of newly diag- whether this mutated ERK2 played a role in the initial
nosed human malignancies (Landis et al., 1999). Inter- transformation of the CMS5 fibrosarcoma, no escape-vari-
estingly, many human sarcomas, such as Ewing's sar- ants of the tumor have been isolated, suggesting that
coma, synovial cell sarcoma, and clear cell sarcoma, the ERK mutation may be essential for maintaining the
are characterized by genetic translocations (EWS-FLI, transformed phenotype (Ikeda et al., 1997). By obviating
SSX-SYT, and EWS-ATFI, respectively) that not only re- the need to transfect a tumor with a neo-antigen, we
sult in transformation but also produce unique mutated were ideally equipped to examine tumor-specific T cell
proteins which may function as tumor-specific antigens. responsiveness in tumor-bearing hosts. We generated
These unique tumor-associated antigens make sarco- syngeneic TCR transgenic mice expressing a T cell re-
mas suitable targets for immunologically based therapy ceptor restricted by H-2Kd and specific for the tumor-
(Linehan et al., 1999). expressing mutated ERK2 (136±144), tERK-I. We used
Many human and experimental tumor-associated an- this TCR transgenic model system to define the number
tigens have recently been identified (van der Bruggen of adoptively transferred tumor-specific T cells neces-
et al., 1991; Wolfel et al., 1995; Ikeda et al., 1997), facili- sary to eradicate an established tumor burden without
tating a focus on generating such tumor-specific im- the potentially detrimental and complicating use of adju-
mune responses. Various vaccination protocols de- vant, cytokines, or immunosuppression. We further de-
signed to increase the responsiveness of the host termined that even in the context of a large tumor burden
which could not be controlled with adoptive immuno-
therapy, the transferred tumor-specific T cells remained§ To whom correspondence should be addressed (e-mail: allen@
immunology.wustl.edu). functional in vivo. These studies definitively show that
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Figure 1. DUC18 Splenocytes Exclusively Express the Transgenic b Chain and Are Predominately Selected into the CD8 Lineage When
Endogenous a and b Rearrangement Is Abrogated
Splenocytes from a transgene-negative (A and D), DUC18 (B and E), and DUC18.SCID (C and F) mice were analyzed for expression of CD4
and CD8 (A±C) or Vb8.3 and CD8 (D±F). The numbers in each quadrant represent the percentage of live lymphocytes staining positive for the
indicated cell surface molecules. DUC18 cells reconstitute the C18 clone specificity without reactivity to nERK-I. In a standard proliferation
assay, naive DUC18 splenocytes specifically proliferate when stimulated with varying concentrations of tERK-I peptide but do not proliferate
when stimulated with nERK-I peptide or a Kd binding control peptide NP-flu (G). tERK-I and nERK-I induce comparable surface stabilization
of H-2Kd as detected by SF1.1.1 mAb staining of TAP-deficient T2-Kd cells (H). These CTL are also capable of specifically lysing CMS5 tumor
targets (I) in vitro. Cell lines grown out of DUC18 mice as described in Experimental Methods retain in vitro specificity for tERK-I peptide-
pulsed P815 targets in a standard 51Cr-release assay (J).
tumor-specific T cells are not globally suppressed in (Ikeda et al., 1997). CMS5 is a methylcholanthrene-
a tumor-bearing host and that abrogating established induced immunogenic fibrosarcoma of BALB/c mice
tumor growth can be achieved by adoptive transfer of lacking viral antigens (DeLeo et al., 1977; Srivastava et
tumor-specific T cells in a dose-dependent manner. Fur- al., 1986) but with a single base pair mutation in the
ther, we show that the eventual limitation of adoptive ERK2 gene that translates into an amino acid difference
immunotherapy is likely to be due to the rapid prolifera- sufficient to function as a unique tumor-rejection antigen
tion of tumor cells and the inadequate localization and (Ikeda et al., 1997). At position 136, the CMS5 tumor±
maintenance of a tumor-specific T cell population. derived ERK2 contains a glutamine, whereas tissues
containing normal ERK2 ubiquitously express an ERK2
protein with a lysine at position 136 (Ikeda et al., 1997).
Hereafter, we refer to the nonamer peptide derived fromResults
CMS5 ERK2(136±144) as tERK-I and the nonamer de-
rived from normal ERK2(136±144) as nERK-I.We generated a murine TCR transgenic line in the
BALB/c background that expresses the rearranged Va10.1
and Vb8.3 genes of the previously described CD81 CTL
DUC18 Mice Express the Transgenic b Chainclone C18 (Ikeda et al., 1997). The transgenic founder line
on Thymocytes and Peripheral CD81 T Cellsis referred to as DUC18, and its H-2Kd-restricted trans-
When compared to transgene-negative littermates,genic T cell receptor is specific for the syngeneic CMS5
fibrosarcoma rejection antigen mutated ERK2(136±144) DUC18 mice have normal thymic and splenic cellularity
Eradication of Established Tumors by CD81 T Cells
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Figure 2. DUC18 Mice Rapidly and Specifically Reject High Doses of Subcutaneous CMS5 Tumor Challenge in a CD8-Dependent Manner
DUC18 mice or transgene-negative littermates were challenged subcutaneously on the hind flank with a high-dose (3 3 106 cells/mouse)
challenge of the MethA fibrosarcoma (A), medium-dose (1.5 3 106 cells/mouse) challenge of the CMS5 fibrosarcoma (B), or high-dose (3 3
106 cells/mouse) challenge of the CMS5 fibrosarcoma (C). Ten DUC18 mice successfully rejected a rechallenge with a second dose (3 3 106)
of CMS5 (D). In (E), mice were depleted of CD41 lymphocytes by weekly intraperitoneal administration of anti-CD4 antibody (GK1.5) or in (F),
of CD81 lymphocytes by administration of anti-CD8 antibody (YTS169.4). Tumor growth is shown as the product of two orthogonal diameters
(mm2) from 2 to 22 days, after which the experimental animals required euthanasia. Each line represents the mean of five animals per group,
with error bars representing standard deviation from the mean. (A), (E), and (F) are each representative of two identical experiments. (B) and
(C) are each representative of more than five similar experiments.
and normal percentages of CD41 and CD81 thymocytes CD8 compartment in the thymus (data not shown) and
in the spleen (Figure 1C). Importantly, in the peripheryand splenocytes without marked skewing toward either
single-positive compartment (Figures 1A and 1B). Im- of a DUC18.SCID, .99% of the TCRb1CD81 are Vb8.31
(Figure 1F). Thus, DUC18 cells are selected into the CD8portantly, 35%±50% of CD81 thymocytes and spleno-
cytes express Vb8.3 in DUC18 mice compared to 10%± lineage when endogenous a and b chain rearrange-
ments are eliminated.12% in transgene-negative littermate controls (Figures
1D and 1E). The percentage of CD41 thymocytes and
splenocytes expressing Vb8.3 is similar between DUC18
and transgene-negative littermate controls. Both com- Cells from DUC18 Mice Recapitulate C18 T Cell
partments of single-positive thymocytes in the DUC18 Clone Specificity
mice primarily consist of cells expressing high levels of Naive splenocytes from DUC18 mice recapitulated the
TCR and exhibiting a mature phenotype (TCRhi, HSAlo; specificity of the C18 T cell clone by specifically prolifer-
data not shown) indistinguishable from transgene-nega- ating when stimulated with mutated ERK2 peptide (136±
tive littermate controls. Additionally, DUC18 mice and 144) tERK-I but not when stimulated with wild-type ERK2
peptide (136±144) nERK-I or a Kd binding control pep-transgene-negative littermates have similar overall splenic
cellularity and similar peripheral T cell surface marker phe- tide, NP-flu (Figure 1G). This specific recognition is due
to TCR specificity and not a differential ability to bind tonotypes characteristic of naive cells (CD62Lhi, CD69lo,
CD252; data not shown). Kd, since both tERK-I and nERK-I stabilize comparable
levels of Kd on the cell surface of TAP-deficient T2-KdWe crossed the DUC18 line onto the SCID background
in order to eliminate endogenous TCR rearrangement cells (Figure 1H). Importantly, CMS5 tumor targets are
efficiently killed in vitro by DUC18 CTL lines, whereas aand obtain a monoclonal population of CMS5-reactive
cells. When compared to the DUC18, cells from the control mastocytoma, P815 and a control fibrosarcoma,
MethA are not (Figure 1I). Finally, CTL lines derived fromDUC18.SCID show a substantial skewing toward the
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Figure 3. An Invasive Lymphocytic Infiltrate Populates the CMS5 Challenge Site in DUC18 Mice
Frozen sections of CMS5 tumor tissue from transgene-negative (A±C) or DUC18 (D±F) mice were stained with hematoxylin and eosin for
visualization of the cellular composition of tumors growing for 2 (A and D), 6 (B and E), or 10 (C and F) days. Tissues were grossly similar
early in tumor growth, with healthy tumor tissue surrounded by few peripheral inflammatory cells (A and D). By day 6 post tumor challenge,
CMS5 tissue from transgene-negative mice was largely healthy with focal lymphocytic infiltration (B), whereas CMS5 tissue from DUC18 mice
was overwhelmingly and destructively populated by lymphocytes (E). By day 10, lymphocytes were limited to the periphery of CMS5 tissue
from transgene-negative mice (C), whereas residual lymphocytes and very sparse tumor tissue was present in DUC18 mice (F). Photographs
were taken under 6303 magnification.
DUC18 mice reconstitute C18 specificity by effectively of the CD81 repertoire specific for CMS5, it is perhaps
not surprising that a CMS5 challenge in these mice islysing tERK-I peptide±pulsed target cells at an ef-
fector:target ratio of 5:1 while remaining nonreactive to rejected easily, rapidly, and without CD41 help.
nERK-I peptide±pulsed targets at the peptide concen-
trations tested (Figure 1J).
An Extensive Lymphocytic Infiltrate Precedes
Tumor Destruction in DUC18 Mice
DUC18 Mice Rapidly and Specifically Reject High We analyzed CMS5 tumor tissue sections from DUC18
Dose Subcutaneous CMS5 Tumor Challenges and transgene-negative littermates throughout the course
We examined the ability of DUC18 mice to respond to of tumor growth. During the early stages of tumor growth
a lethal tumor challenge by subcutaneously inoculating (day 2), CMS5 appears histologically similar in both
DUC18 or transgene-negative littermates with various groups of mice (Figures 3A and 3D). These early tumors
doses of tumor cells. DUC18 mice were fully capable of are pseudoencapsulated and contain healthy tumor
rejecting lethal challenges (1.5 3 106 and 3 3 106 cells/ cells growing in uniform, orderly bundles among abun-
mouse) of CMS5 (Figures 2B and 2C) and remained capa- dant matrix, with only a few inflammatory cells on the
ble of rejecting a second lethal challenge of CMS5 (Fig- periphery of the tumor. Six days after the tumor chal-
ure 2D). Interestingly, CMS5 rejection in the DUC18 mice lenge, normal transgene-negative littermates have lympho-
occurred consistently 10±12 days after tumor challenge. cytic foci primarily at the tumor perimeter (Figure 3B),
These mice were observed for 12 months and did not while DUC18 tumor tissue is invasively infiltrated with
develop tumors, nor did they exhibit any gross autoim- lymphocytes and healthy tumor cells are scarce (Figure
mune abnormalities (data not shown). In vivo depletion 3E). Ten days after challenge, transgene-negative mice
of the CD41 or CD81 T cell subsets showed that tumor have robust, hypercellular tumor growth (Figure 3C),
rejection in the DUC18 mice was not dependent on the while rejection is resolving in DUC18 mice, leaving apo-
CD41 T cells but was highly dependent on the CD81 T ptotic nuclei, residual lymphocytes, and collagenous in-
cells (Figures 2E and 2F). Additionally, the ability to reject tercellular scarring (Figure 3F).
CMS5 in vivo was tumor specific, since the DUC18 mice
were unable to reject a high-dose challenge of MethA
fibrosarcoma cells and in fact succumbed to tumor bur- Adoptive Transfer of DUC18 Splenocytes Protects
Normal BALB/c Recipients from Subsequentdens greater than their transgene-negative littermates
(Figure 2A). This result suggests the skewing of the CMS5 Challenge
We sought to define the threshold of tumor-specificDUC18 peripheral population of CD81 T cells to be 35%±
50% Vb8.31 created mice with a diminished total reper- T cell effectors necessary to eliminate a lethal tumor
challenge by titrating the number of tumor-specific Ttoire and lends credence to the notion that specific sur-
veillance does occur in the normal host. With 35%±50% cells present in the host prior to tumor challenge. We
Eradication of Established Tumors by CD81 T Cells
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Figure 4. Adoptive Transfer of 12±30,000 Tumor-Specific DUC18 T Cells to a Normal Host Is Sufficient to Reject a Subsequent Tumor Challenge
DUC18 splenocytes (closed symbols) or littermate splenocytes (open symbols) were adoptively transferred through the lateral tail vein into
normal BALB/c recipients (A±I). The x axis values are day post tumor challenge, and the y axis values are tumor size (mm2). The numbers in
each panel represent the number of Vb8.31CD81 T cells transferred to each recipient. Each line represents the tumor growth of one individual
mouse over 20±22 days, after which the experimental animals required euthanasia. (A)±(E) show three mice/group and are representative of
at least two experiments at each dose. (F)±(G) show ten individual mice that received DUC18 splenocytes at each dose.
adoptively transferred DUC18 splenocytes or trans- Adoptive Immunotherapy of Established Tumors
Requires More Tumor-Specific T Cells Thangene-negative splenocytes intravenously to normal
BALB/c recipients 24 hr prior to CMS5 tumor challenge Rejection of a Subsequent Tumor Challenge
In most studies of protective immunity against tumors,(Figure 4). Surprisingly, transferring as few as 12±30,000
tumor-specific cells (Figures 4F and 4G) was sufficient vaccination or adoptive effector cell transfer has been
prior to or simultaneous with the tumor challenge. Ato protect 9/10 mice from a subsequent high-dose tumor
challenge. A 10-fold reduction in the number of specific more relevant immunotherapeutic goal is to be able to
generate protective immunity in a host with an existingcells transferred resulted in only 2/10 of the mice being
protected from subsequent tumor challenge (Figures 4H malignancy. Appropriate immunization can generate or
enhance CTL responses (Old et al., 1962; Boon et al.,and 4I). Notably, in each experiment, the CMS5 chal-
lenge did initially grow to a diameter of 5±7 mm after 1994; Pardoll, 1998). However, the inadequacy of most
responses is evidenced by continued tumor outgrowth.6±8 days before being completely rejected 10±12 days
after tumor challenge. We sought to examine the threshold of tumor-specific
T cells required to regress or reject tumors that hadTo establish that CMS5 rejection was dependent only
on the adoptively transferred CD81 T cells, we trans- been established for varying lengths of time in order to
more clearly design future immunotherapy approachesferred DUC18 splenocytes that had been selectively de-
pleted in vitro of B cells or CD41 T cells. While recipients capable of generating and maintaining tumor-specific
immunity.of transgene-negative splenocytes succumbed to rapid
and fatal CMS5 tumor growth, the recipients of DUC18 We established CMS5 tumors in normal BALB/c hosts
for 3, 5, 7, 11, or 14 days before transferring naive T cellsplenocytes, CD41 T cell±depleted DUC18, or B cell±
depleted DUC18 splenocytes rapidly rejected the tumor populations intravenously in a single injection. Remark-
ably, tumors that had been established for 3 days werechallenge (data not shown). To confirm that calculating
the number of tumor-specific T cells transferred based rejected by the transfer of splenocytes containing 3 3
104 DUC18 T cells (Figure 5B). Tumors that were allowedon the number of Vb8.31CD81 T cells in the inoculum
was an accurate measure and to eliminate any involve- to grow for an additional 48 hr required 3 3 106 DUC18 T
cells for rejection (Figure 5F). The rejection consistentlyment of T cells expressing endogenously rearranged a
chains, we transferred 3 3 104 Vb8.31CD81 T cells from occurred 10±12 days after the adoptive transfer. CMS5
growth for 7 (Figures 5G±5J), 11, or 14 days prior to Ta DUC18.SCID mouse into normal BALB/c recipients
and subsequently challenged the recipients with CMS5. cell transfer was unaffected by the transfer of 3,000,000
tumor-specific DUC18 T cells (data not shown), andImportantly, 4/5 of the recipients rejected the CMS5
tumor challenge, confirming that 30,000 tumor-specific CMS5 tumors were not rejected at any time point by
transfer of transgene-negative T cells (Figures 5A, 5C,CD81 T cells are sufficient to reject a subsequent tumor
challenge in this model (data not shown). and 5G; data not shown). Rejection or regression of an
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Figure 5. Adoptive Immunotherapy of Established Tumors Is Successful
BALB/c mice were challenged subcutaneously with 3 3 106 CMS5 tumor cells. Mice were subsequently treated on day 3 (A and B), 5 (C±F),
or 7 (G±J) with adoptively transferred splenocytes from naive BALB/c (A, C, and G) or naive DUC18 (B, D±F, and H±J) splenocytes. The x axis
values are day post tumor challenge, and the y axis values are tumor size (mm2). The numbers above each panel represent the number of
Vb8.31CD81 T cells transferred to each recipient. Arrows indicate the day of adoptive transfer. The data is representative of two similar
experiments.
established CMS5 tumor that is normally highly aggres- T cells remained sufficiently functional in the presence
of a 7 day tumor to eliminate a smaller tumor burdensive and lethal after 4 weeks of growth represents a
notable immunotherapeutic success and highlights an while having no detectable effect on the larger tumor
burden. This functional response indicated that in theimportant dose dependency of that success.
8±10 days post transfer required to reject the estab-
lished 3 day tumors on the left flank, the larger tumorAdoptive Immunotherapy of Established Tumors
on the right flank did not appreciably cause tolerancein Mice Bearing Two Temporally Distinct CMS5
or suppression of the transferred DUC18 T cells. In orderTumor Challenges Effectively Eliminates
to determine whether the T cells would remain functionalthe Smaller Tumor Burden
at later stages of tumor growth and when exposed toWe further investigated whether the inability to reject a
the large tumor burden for an extended period of time,CMS5 tumor that had grown for seven or more days was
we transferred DUC18 T cells into BALB/c mice carryingdue to a tumor-induced dysfunction of the transferred T
7 day CMS5 tumors on the right flank. We then waitedcell population. BALB/c mice were cochallenged with
5 days until the right flank tumors had been establishedtemporally separate CMS5 tumor inocula prior to adop-
for 12 days and the transferred T cells had been exposedtive transfer of DUC18 T cells in order to ascertain
to the large tumor burden for 5 days. On day 12, wewhether the transferred tumor-specific T cells remained
challenged the mice on the left flank with the CMS5functional against a small tumor burden in the presence
tumor and observed the tumor growth on the doublyof a large tumor burden. Groups of BALB/c mice bearing
challenged BALB/c transfer recipients. Again, while the7 day CMS5 tumors on the right flank (Figure 6A), 3 day
mice remained unable to reject the 7 day tumors estab-CMS5 tumors on the left flank (Figure 6B), or both 7 and
lished prior to the adoptive transfer (Figure 6C), doubly3 day tumors were treated with 3 3 106 DUC18 T cells
challenged recipients of the DUC18 T cell transfer were(Figures 6A and 6B). Notably, the adoptive transfer suc-
capable of rejecting the second CMS5 tumor challengecessfully eradicated the 3 day CMS5 tumors in the co-
given on day 12 (Figure 6D). This rejection was completechallenged mice, while the 7 day CMS5 tumors contin-
despite the exposure of the adoptively transferred Tued to grow progressively on the opposite flank in the
same mice. These results indicated that the transferred cells to the environment of the larger tumor for 5 days
Eradication of Established Tumors by CD81 T Cells
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Figure 6. Adoptive Immunotherapy Effec-
tively Eliminates Small Tumors but Not Large
Tumors in Mice Bearing Temporally Distinct
Tumor Challenges
A schematic time line shows the cochallenge
experiments.
Top: BALB/c mice were challenged subcuta-
neously with 3 3 106 CMS5 tumor cells on
day 0 (A) and/or day 4 (B). Groups of five mice
were challenged on day 0 only (circles), day
4 only (triangles), or cochallenged on both
day 0 and day 4 (squares). Mice were sub-
sequently treated on day 7 with an intrave-
nous transfer of either HBSS (open symbols)
or DUC18 splenocytes containing 3 3 106
Vb8.31CD81 T cells (closed symbols).
Bottom: BALB/c mice were challenged sub-
cutaneously with 3 3 106 CMS5 tumor cells
on day 0 (C) and/or day 12 (D). Groups of
mice were challenged on day 0 only (circles),
day 12 only (triangles), or cochallenged on
both day 0 and day 12 (squares). Mice were
treated on day 7 with an intravenous transfer
of either HBSS (open symbols) or DUC18
splenocytes containing 3 3 106 Vb8.31CD81
T cells (closed symbols).
prior to the secondary challenge. Interestingly, the rejec- the tumor site. Four days after receiving a transfer of
DUC18 splenocytes containing 3 3 106 Vb8.31CD81 Ttion of the day 12 CMS5 challenge was more rapid in
the doubly challenged mice than in mice that did not cells, a lymphocyte population was observed at the pe-
riphery of both the early (4 day) and late (7 day) tumorshave a 7 day established tumor but received the T cell
transfer 5 days prior to the secondary challenge. While (data not shown). However, by 6 days after the transfer
of T cells, the lymphocyte population had disappearedthe doubly challenged mice showed barely any second-
ary tumor growth, the singly challenged mice that re- from the site of the late tumor (Figure 7A) while appearing
to have expanded, encircled, and infiltrated the earlyceived the adoptive transfer 5 days prior to the CMS5
challenge still required 10±12 days to reject the tumor tumor (Figure 7B). Eight to ten days after the DUC18
transfer, the early tumor had been rejected, leaving be-challenge. This difference in the time required to reject
the left-flank tumor challenge was not simply due to hind healthy skin and collagenous matrix. The late tu-
mors treated with DUC18 transfer continued to growconcomitant immunity, since the doubly challenged re-
cipients of the control transfer showed no difference progressively, showed lymphocytes only in scattered
patches of central necrosis, and did not display evi-from the singly challenged recipients of the control
transfer in terms of tumor growth. This observation dence of uniform lymphocytic infiltration (data not
shown).raises the interesting possibility that the adoptive trans-
fer augmented a meager immune response occurring
naturally in the mice bearing the 7 day tumors.
Discussion
Rejection of Early Established Tumors by Adoptive
Transfer Is Preceded by a Lymphocytic Infiltration We have established a distinctive experimental tumor
model in which we have utilized a well-characterizedof the Tumor Site
Histological examination of the site of tumor challenge fibrosarcoma, CMS5, its known tumor-rejection antigen,
mutated ERK2(136±144), and a novel syngeneic TCRin mice bearing 4 day or 7 day established tumors re-
vealed an interesting difference in the appearance of transgenic mouse, DUC18, to examine tumor-specific T
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of the transferred cells to reject a 7 day tumor was not
due to an inherent tumor-induced T cell dysfunction.
These results instead highlight an important kinetic dis-
parity between tumor cell growth and the generation of a
tumor-specific response and underscore the possibility
that advanced tumors may retain their kinetic prolifera-
tive advantage by maintaining a hostile host environ-
ment unsuitable for immune infiltration. After adoptive
transfer of tumor-specific CD81 T cells into hosts bear-
ing early tumor burdens, an invasive lymphocytic infiltra-
tion preceded tumor eradication. However, transfer of
tumor-specific CD81 T cells into hosts bearing later tu-
mor burdens resulted in only a transient lymphocytic
presence at the site of tumor challenge.
Previous reports have demonstrated that two injec-
tions of 2.5 3 107 irradiated CMS5 cells were required
to protect BALB/c mice from a subsequent low-dose
challenge of 7.5 3 104 CMS5 cells (Srivastava et al.,
1986) and that coinjection of IL-2-producing CMS5 cells
with 8 3 105 parental CMS5 cells could prevent tumor
outgrowth (Gansbacher et al., 1990). Additionally, mice
immunized with tERK-I-pulsed splenocytes were only
protected from CMS5 challenge when simultaneously
treated with IL-12 (Ikeda et al., 1997). Taken in this con-
text, the minimal number of 30,000 tumor antigen±
specific T cells required to protect recipients in our sys-
tem from a highly tumorigenic and lethal subsequent
challenge is impressive. Since approximately 0.2%±
0.5% of peripheral cells in unirradiated hosts originate
from the adoptive transfer (Kearney et al., 1994), the
tumor-specific frequency of cells in our adoptive transfer
system can be estimated to be approximately 1 in 2000
CD81 T cells. The ability to generate an effective anti-
tumor attack in our adoptive transfer model is promising
evidence that immunotherapy designed to augment the
frequency of tumor-specific effectors may be feasible.Figure 7. A Ring of Lymphocytes Surrounds CMS5 Tumor Tissue
Many molecular mechanisms have been proposed toin Recipients of DUC18 Adoptive Transfer
explain the masterful escape of a tumor from surveil-BALB/c mice carrying day 4 established tumors received a normal
lance and elimination by the competent specific immuneBALB/c adoptive transfer (A) or a DUC18 adoptive transfer (B). Six
system. Peripheral tumors may be ignored by the spe-days after the adoptive transfer, tumors were excised and frozen
cific immune system (Ochsenbein et al., 1999), may in-sections stained with hematoxylin and eosin. Photographs are under
403 magnification. duce peripheral T cell anergy (Gajewski et al., 1995; Liu
et al., 1996; Staveley-O'Carroll et al., 1998), or may cause
specific biochemical alterations in responding T cells
cell function in vivo without the addition of cytokines, (Mizoguchi et al., 1992; Nakagomi et al., 1993; Salvadori
adjuvant, or immunosuppression. and Zier, 1996). However, the ultimate consequence of
Naive cells from our DUC18 transgenic mice were each potential escape mechanism may be an insufficient
capable of proliferating in vitro in response to tERK-I, tumor-specific T cell response, which results in a detri-
and DUC18 mice rapidly and specifically rejected lethal mental kinetic disparity between the growth of the malig-
challenges of CMS5 tumor cells. DUC18 cells retained nancy and the accumulation of host anti-tumor effector
CTL activity as detected by in vitro chromium-release cells.
assays after rejecting the CMS5 challenge and were Eliminating the kinetic disparity between malignant
fully capable of rejecting a second in vivo CMS5 tumor and immune effector growth will require generating and
challenge. In our studies, adoptive transfer of from 1.2 3 maintaining the tumor-specific response and will be an
104 to 3.0 3 104 tumor-specific T cells was sufficient to important consideration in future immunotherapeutic
protect recipients from a subsequent lethal challenge approaches. We invariably observed a 10±12 day period
of 3 3 106 CMS5 tumor cells. While a CMS5 tumor al- in which the CMS5 tumors grew progressively before
lowed to grow and establish for 3 days in vivo was easily being completely rejected in DUC18 mice and adoptive
rejected by 3 3 104 adoptively transferred tumor-specific transfer recipients. Ochsenbein et al. recently reported
T cells, a 100-fold increase in adoptively transferred the same consistent rejection time frame in an indepen-
tumor-specific T cells was required to reject tumors that dent model utilizing C57BL/6 mice and the MC57G sar-
were allowed to grow for just an additional 48 hr. Tumors coma transfected with the LCMV glycoprotein (Och-
which were allowed to grow for 7 days in vivo were senbein et al., 1999). These results are consistent with
not rejected by adoptively transferred tumor-specific the evidence from viral model systems in which the
T cells. However, adoptively transferred T cells were generation of an effective CTL response involving T cell
capable of rejecting 3 day tumors in mice bearing both activation, replication, and accumulation lasts about 1
week (Ahmed and Gray, 1996). Studies by Ochsenbein3 and 7 day CMS5 tumors, suggesting that the inability
Eradication of Established Tumors by CD81 T Cells
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et al. also have shown that the timing and duration of cells are unable to maintain their presence at the tumor
tumor antigen stimulus in the secondary lymphoid or- site at later time points in tumor progression. Shrikant
gans are critical for the priming and maintenance of an and Mescher recently reported model antigen±specific
adequate anti-tumor response. Further, while a single T cells that recognize antigen at the site of tumor growth,
vaccination attempt to generate an effective anti-tumor exit to the lymph node, and fail to return to the site of
response may not cause established tumor eradication, tumor growth (Shrikant and Mescher, 1999). Alterna-
multiple vaccinations over time may cause gradual re- tively, Stavely-O'Carroll et al. have shown that in a model
gression (Ochsenbein et al., 1999). In our system, estab- of B cell lymphoma utilizing A20 cells transfected with
lished tumor regression and rejection required 100 times the HA model antigen, HA-specific T cells show pheno-
more tumor antigen±specific T cells to reject a 5 day typic changes consistent with antigen recognition but
tumor than a 3 day tumor, and this rejection still required are effectively anergized and unable to eliminate or af-
a 10±12 day window of time after the adoptive T cell fect tumor growth (Staveley-O'Carroll et al., 1998). Simi-
transfer. Tumors allowed to grow for 7 or more days lar tumor antigen unresponsiveness has been observed
before the adoptive T cell transfer were not therapeuti- in human melanoma patients with metastatic disease
cally controlled, suggesting again the importance of di- (Lee et al., 1999). Our own data suggest that tumor-
recting any immunotherapeutic protocol toward elimi- specific T cell tolerance does not account for the inability
nating early the kinetic disparity between tumor growth of DUC18 T cells to reject late established tumors, since
and the immune attack and maintaining the tumor-spe- these cells are capable of eradicating a small tumor
cific response over time. The importance of this obser- burden contained within the same host. Further, even
vation is corroborated by the recent report from Cordaro with extended exposure to a large tumor burden, DUC18
et al. suggesting that the ratio of antigen-specific ef- T cells are still capable of rejecting a subsequent sec-
fector T cells to antigen-expressing tumor cells deter- ondary CMS5 tumor challenge. Instead, our results are
mines the success of adoptive immunotherapy (Cordaro most consistent with the hypotheses that tumor tissue
et al., 2000). becomes less accessible to T cell infiltration or that
Many tumors, including sarcomas, have characteristic tumor-specific T cell maintenance is not sufficient as
cytogenetic abnormalities that may result in the produc- tumors continue to grow and establish. In our model
tion of unique tumor-associated antigens (Linehan et al., system, the dose-dependent successful regression of
1999). Our results suggest that adoptive immunotherapy progressively growing sarcomas by a single adoptive
may be an effective treatment for solid tumors harboring transfer of tumor-specific T cells emphasizes the impor-
such tumor-specific antigens. Although the antigen in tance of concentrating immunotherapeutic strategies on
our system differs from the ubiquitously expressed self- shifting the kinetic balance away from the malignancy
ERK2(136±144) at only one amino acid, we did not ob- and toward the immune response. We will utilize this
serve central deletion of the transgenic T cells in the valuable paradigm to further analyze tumor-specific ef-
thymus and we did not observe tolerance, peripheral fector maintenance, function, and location over time to
anergy, or unresponsiveness as has been seen in other dissect the therapeutic modalities most efficacious for
systems utilizing model or self-antigens. However, rejec- stimulating the tumor-specific effector response to over-
tion of the established CMS5 tumors in our system was come malignant outgrowth.
dose and time dependent. While early CMS5 tumors
were rejected by the transfer of tumor-specific cells,
Experimental Methodslate CMS5 tumors were not. The inability to reject the
late CMS5 tumors was not due to specific tolerization
Cell Linesof the tumor-specific cells, since adoptive transfer of
C18 is a CD81 T cell clone restricted by H-2Kd and specific for theDUC18 T cells into mice cochallenged with both an early
CMS5 tumor-rejection antigen mutated ERK2(136±144) as describedand late CMS5 tumor was successful in eradicating the
previously (Ikeda et al., 1997). T2-Kd cells were generated by stably
small early tumor. These results suggest that effective transfecting human TAP-deficient T2 cells with murine H-2 Kd cDNA
immunotherapy may be most effective when used in (kind gift of Ted Hansen). The fibrosarcoma cells CMS5 (DeLeo et
conjunction with chemotherapeutic, surgical reduction al., 1977) and MethA as well as the mastocytoma P815 and the
of the tumor burden or other combined modalities. T2-Kd cells were propagated in vitro in tissue culture flasks con-
taining RPMI 1640 supplemented with 10% FCS (HyClone, Logan,Adoptive transfers have been unsuccessful in eliminat-
UT), 1mM Glutamax (Life Technologies, Gaithersburg, MD), and 50ing established tumors in several other model systems.
mg/ml gentamicin. CD81 T cell lines from the DUC181 mice (de-However, coinjection of tumor-specific CTL and the tu-
scribed below) were generated by stimulating 3±5 3 105 DUC181mor at the same time point in these systems prevented
splenocytes per well with peptide-pulsed BALB/cAnNCr (NCI) sple-or reduced tumor outgrowth (Wick et al., 1997; PreÂ vost-
nocytes per well. The BALB/cAnNCr (referred to as BALB/c) stimula-Blondel et al., 1998). These reports, in combination with
tor cells were pulsed with 1 mM tERK-I peptide for 1 hr at 378C,
our data showing time- and dose-dependent CD81 T washed three times, and irradiated before culturing 4 3 106 per well
cell±mediated tumor rejection, suggest that the window with the DUC181 cells in 24-well plates. The lines were grown for
of time in which tumor-specific CTLs may eradicate a 10±12 days before restimulation in RPMI 1640 supplemented with
tumor is very limited. 10% FCS (HyClone, Logan, UT), 5 3 1025 M 2-ME, 1 mM Glutamax,
2.5 mM HEPES, 50 U/ml penicillin, 50 mg/ml streptomycin, and 50Several factors may account for the finite window of
mg/ml gentamicin.opportunity to eradicate the tumors in our system. It
has been suggested that as the time of tumor bearing
increases, antigen-specific tolerance may be induced, Generation of Transgenic Mice
tumor tissue may become inaccessible, or tumor anti- Va and Vb gene usage was determined for the C18 T cell clone
gen±specific T cell priming and maintenance may de- using FACS analysis and RT-PCR as described previously (Hsu et
crease. Our results indicate that antigen-specific toler- al., 1996). Va10.1 V-J and Vb8.3 V-D-J segments were amplified
ance is not operating in our system. However, our results by RT-PCR, and the gene fragments were cloned into pBluescript
(Stratagene, La Jolla, CA) and sequenced using ABI Dye Terminatorare consistent with the possibility that tumor-specific T
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Cycle Sequencing (Perkin-Elmer, Foster City, CA). Sequence analy- washed twice in HBSS, and stained for Kd expression with SF1.1.1
before FACS analysis.sis showed that the C18 T cell clone utilized Va10.1/Ja48 and Vb8.3/
Db2.1/Jb2.6 gene segments. PCR of genomic DNA from the C18 T
cell clone utilizing a Ja50-specific sense oligo and 59 intron-specific 51Cr-Release Assay
anti-sense oligo confirmed that only one a chain rearranged in this Cytotoxic activity was assessed by a 4 hr chromium-release assay.
clone, leaving one chromosome in germline configuration (data Target cells were radiolabeled with 100±150 mCi Na2(51Cr)O4 (Amer-
kindly provided by Ching-Yu Huang and Osami Kanagawa). The sham) for 90 min at 378C in HBSS with 25% FCS. Targets were
V-Ja and V-D-Jb exon cassettes were cloned into TCR a and b washed three times and 104 target cells were mixed with effector
shuttle vectors (Ho et al., 1994), and the completed minigene con- cells to generate multiple E:T ratios and incubated in a total volume
structs were coinjected into BALB/c pronuclei in the Department of of 200 ml in 96-well U-bottom plates for 4 hr at 378C, 5% CO2. For
Pathology Transgenic Core Facility as previously described (Hogan assays in which exogenous peptide was loaded, P815 target cells
et al., 1986). Mice were screened by PCR for cointegration of the a were utilized and the indicated concentration of peptide was present
and b minigene constructs and by FACS for transgenic TCR expres- throughout the 4 hr assay. Each experimental condition was set up
sion. One founder mouse was identified and his progeny were bred in triplicate and chromium release was determined by quantitation
to BALB/c or C.B-17scid/scid mice (Custer et al., 1985) (kind gift of Emil of g-irradiation in 100 ml of supernatant/well. Percent specific lysis
R. Unanue). Transgenic progeny are hereafter referred to as DUC18 was determined as 100 3 [(cpm experimental wells 2 cpm sponta-
transgenic mice and were identified by PCR amplification of the neous release)/(cpm maximum release 2 cpm spontaneous re-
C18 b transgene from tail DNA. All mice were housed in a specific lease)]. Maximum release was determined by detergent lysis of tar-
pathogen-free barrier facility at Washington University. gets. Spontaneous release was ,15% of maximum.
Antibody Production and In Vivo Depletion Adoptive Transfer and In Vivo Tumor Challenge
GK1.5 (a-CD4) and YTS169.4 (a-CD8a) hybridomas were utilized for Single-cell suspensions of DUC18 splenocytes were prepared in
ascites production in C.B-17scid/scid mice. Ascites was partially puri- HBSS, washed twice, and counted. Transferred populations were
fied by salt fractionation with saturated ammonium sulfate and the normalized for Vb8.3 and CD8 dual positivity as determined by FACS
precipitate dialyzed against PBS. For in vivo depletion of CD41 or prior to intravenous injection in HBSS. For in vivo tumor challenges,
CD81 lymphocytes, 50 ml ascites was injected intraperitoneally 7 tumor cells were removed from culture flasks by trypsinization and
days prior to tumor challenge and every 7 days thereafter for the washed twice in PBS. Subcutaneous tumor challenges were given
duration of the experiment. Depletion was confirmed by FACS analy- in a total volume of 200 ml PBS using a 27G needle. Tumor growth
sis of peripheral blood 10 and 20 days after the initial injection was measured every 48 hr using a caliper and was recorded as the
and by FACS analysis of splenocytes at the termination of each product of two orthogonal diameters (a 3 b). The first diameter was
experiment. Subset depletion was .90% complete (data not identified as the longest surface length (a), with the second diameter
shown). being the subsequent orthogonal width (b).
Peptides Histology
The peptides used in this study were synthesized by standard FMOC CMS5 tumors were excised, embedded in O.C.T. compound (Miles,
chemistry using a multiple peptide synthesizer (Symphony/Multi- Elkhart, IN), and flash-frozen in liquid nitrogen. Serial 4 mm sections
plex, Protein Technologies, Tuscon, AZ). All peptides were HPLC were fixed in acetone and stained with hematoxylin and eosin. Sec-
purified, and analyzed by mass spectrometry (Washington Univer- tions were analyzed histologically for cellularity, differentiation, mi-
sity Mass Spectrometry Resource) for purity. Peptide concentration totic figures, vascularity, necrosis, and matrix quality.
was determined by amino acid analysis (model 6300, Beckman,
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